Tirzepatide research peptide is supplied to qualified Canadian institutions as a characterized laboratory material for in vitro incretin-receptor studies. The compound is a 39-amino-acid synthetic peptide bearing a C20 fatty diacid conjugate (LY3298176).

In vitro, the diacid extends availability through albumin binding, and the peptide is used as a comparator in GIP and GLP-1 receptor signalling tests. Typical designs record receptor occupancy or second-messenger readouts in cells expressing those receptors. This listing describes receptor pharmacology in experimental systems only.

The material is offered as a lyophilized vial. Identity data (CAS 2023788-19-2, formula C225H348N48O68, molecular weight 4813.5 g/mol, PubChem CID 166567236) are listed on the specification table. Store lyophilized at −20 °C, protected from light, and handle under the receiving institution's chemical-hygiene plan.

Lots are sourced from a GMP-aligned peptide manufacturing partner and released against the stated HPLC purity for that lot (≥99% by HPLC, lot-specific). Identity, chromatographic purity, and related analytical results are documented on the lot certificate of analysis (COA). Retain the COA with the inventory record.

This listing is a research-use-only peptide offered to qualified Canadian institutions for in vitro and laboratory use. Purchasing access is limited to verified Canadian research institutions; individual consumer accounts are not accepted. It is not for human or veterinary use, is not intended for diagnostic procedures, and has not been evaluated or authorized by Health Canada as a drug, diagnostic, or medical product.